According to filings with the U.S. Securities and Exchange Commission, Vergent Bioscience, Inc. is raising up to $31,957,273.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Vergent Bioscience, Inc.
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergents lead investigational compound, abenacianine for injection (VGT-309), is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating abenacianine for injection in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

To learn more about Vergent Bioscience, Inc., visit https://www.vergentbio.com/
Vergent Bioscience, Inc. Linkedin Page: https://www.linkedin.com/company/vergent-bioscience/

Contact:
John Santini, President
952-426-3772
https://www.linkedin.com/in/john-santini-6264011/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.